PALO ALTO, Calif., March 23 /PRNewswire-FirstCall/ -- Avicena Group, Inc. , a late stage biotechnology company focused on commercializing its proprietary cellular energy modulation technology, announced that Chief Executive Officer Dr. Belinda Tsao-Nivaggioli will host a live webcast and conference call on Monday, March 26, 2007, at 11:00 a.m. Eastern Time, to discuss this week's announcement on the initiation of patient enrollment in a Phase III Parkinson's disease trial funded by the National Institute of Neurological Disorders (NIND), a division of the National Institutes of Health (NIH).
The live webcast can be accessed at Avicena's corporate website at www.avicenagroup.com. Interested parties without internet access or wishing to ask questions may dial the domestic U.S./Canada number (877) 407-0789, or the international number (201) 689-8562. Telephonic and audio webcast replays of the call will be available for one week and six months, respectively. Callers may access the telephonic replay archive through April 2, 2007, by dialing (877) 660-6853 in the U.S./Canada or (201) 612-7415 internationally (Account Number 3055 and Conference ID 235697). The audio webcast will be archived at www.avicenagroup.com through September 25, 2007.
ABOUT AVICENA
Avicena Group, Inc. is a late stage biotechnology company focused on developing products based on its proprietary understanding of the regulation of cellular energy processes. The company's core technologies, supported by a robust IP portfolio, have broad applications in both pharmaceuticals and dermaceuticals. Avicena's pharmaceutical program centers on rare neurological disorders (orphan diseases). The company is currently analyzing data from its Phase IIb/III trial in ALS (Amyotrophic Lateral Sclerosis, or Lou Gehrig's disease). Near term, Avicena intends to initiate a Phase III trial in Huntington's disease in addition to the Phase III trial in Parkinson's disease described in this release. Avicena's science is well established and its products are safe and well tolerated. Unlike traditional biotechnology companies, Avicena's clinical programs are largely funded by government and non-profit organizations. Avicena presently derives revenue from the sale of proprietary ingredients to skin care manufacturers.
Contact: The Ruth Group (on behalf of Avicena Group) John Quirk / Sara Ephraim / (investors) (646) 536-7029 / 7002 jquirk@theruthgroup.com or sephraim@theruthgroup.com Janine McCargo / Jason Rando (media) (646) 536-7033 / 7025 jmccargo@theruthgroup.com or jrando@theruthgroup.com
Avicena Group, Inc.CONTACT: Investors, John Quirk, +1-646-536-7029, orjquirk@theruthgroup.com, or Sara Ephraim, +1-646-536-7002, orsephraim@theruthgroup.com; Media, Janine McCargo, +1-646-536-7033, orjmccargo@theruthgroup.com, or Jason Rando, +1-646-536-7025, orjrando@theruthgroup.com, all of The Ruth Group on behalf of Avicena Group
Web site: http://www.avicenagroup.com/
